CPN1 Polyklonaler Antikörper

CPN1 Polyklonal Antikörper für WB, IHC, IF/ICC, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, IF/ICC, ELISA

Konjugation

Unkonjugiert

Publikationen

2

Kat-Nr. : 13385-1-AP

Synonyme

Kininase-1, Kininase 1, EC:3.4.17.3, CPN, Arginine carboxypeptidase

---

Galerie der Validierungsdaten

• 

  WB analysis of Raji using 13385-1-AP

  Raji cells were subjected to SDS PAGE followed by western blot with 13385-1-AP (CPN1 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 13385-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 13385-1-AP (CPN1 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human liver cancer using 13385-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer using 13385-1-AP (CPN1 antibody) at dilution of 1:100 (under 10x lens).

• 

  IHC staining of human liver cancer using 13385-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer using 13385-1-AP (CPN1 antibody) at dilution of 1:100 (under 40x lens).

• 

  IF Staining of COLO 320 using 13385-1-AP

  Immunofluorescent analysis of COLO 320 cells using 13385-1-AP (CPN1 antibody) at dilution of 1:25 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HepG2-Zellen, Raji-Zellen
• Erfolgreiche Detektion in IHC: humanes Leberkarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
• Erfolgreiche Detektion in IF/ICC: COLO 320-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:6000
• Immunhistochemie (IHC): IHC : 1:20-1:200
• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• IHC: See 2 publications below

Produktinformation

13385-1-AP bindet in WB, IHC, IF/ICC, ELISA CPN1 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: CPN1 fusion protein Ag4035
• Vollständiger Name: carboxypeptidase N, polypeptide 1
• Berechnetes Molekulargewicht: 458 aa, 52 kDa
• Beobachtetes Molekulargewicht: 40~50 kDa
• GenBank-Zugangsnummer: BC027897
• Gene symbol: CPN1
• Gene ID (NCBI): 1369
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Human carboxypeptidase N (CPN), a member of the CPN/E subfamily of "regulatory" metallo-carboxypeptidases, is an extracellular glycoprotein synthesized in the liver and secreted into the blood, where it controls the activity of vasoactive peptide hormones, growth factors and cytokines by specifically removing C-terminal basic residues. Normally, CPN circulates in blood plasma as a hetero-tetramer consisting of two 83 kDa (CPN2) domains each flanked by a 48 to 55 kDa catalytic (CPN1) domain. The C terminal region of the CPN1 subunit differs from all other family members in that it contains numerous basic residues. Proteolysis at these sites apparently happens either constitutively in the blood or during processing and secretion from the liver.

Publikationen

Species	Application	Title
human	IHC	Front Pharmacol; High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses.; Authors - Ranliang Cui
human	IHC	Cancer Cell Int; Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer; Authors - Ranliang Cui